These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 22183107

  • 21. Response evaluation with 18F-FDG PET/CT in metastatic breast cancer patients treated with Palbociclib: first experience in clinical practice.
    Taralli S, Lorusso M, Scolozzi V, Masiello V, Marazzi F, Calcagni ML.
    Ann Nucl Med; 2019 Mar; 33(3):193-200. PubMed ID: 30569442
    [Abstract] [Full Text] [Related]

  • 22. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [Abstract] [Full Text] [Related]

  • 23. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
    Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS.
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [Abstract] [Full Text] [Related]

  • 24. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, Menzies AM.
    Ann Oncol; 2018 Oct 01; 29(10):2115-2120. PubMed ID: 30137228
    [Abstract] [Full Text] [Related]

  • 25. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
    Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G.
    J Nucl Med; 2013 Mar 01; 54(3):333-40. PubMed ID: 23401605
    [Abstract] [Full Text] [Related]

  • 26. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.
    Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K.
    Jpn J Radiol; 2022 Jan 01; 40(1):75-85. PubMed ID: 34287739
    [Abstract] [Full Text] [Related]

  • 27. Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer.
    Oh JK, Chung YA, Kim YS, Jeon HM, Kim SH, Park YH, Chung SK.
    Biomed Mater Eng; 2014 Jan 01; 24(1):1173-84. PubMed ID: 24212011
    [Abstract] [Full Text] [Related]

  • 28. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA.
    Radiology; 2012 Apr 01; 263(1):53-63. PubMed ID: 22438441
    [Abstract] [Full Text] [Related]

  • 29. Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?
    Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A, Yoshihara S, Fujimori Y, Yamakado K.
    Eur Radiol; 2019 Jul 01; 29(7):3935-3944. PubMed ID: 30899979
    [Abstract] [Full Text] [Related]

  • 30. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP.
    Eur J Cancer; 2020 Feb 01; 126():11-20. PubMed ID: 31891878
    [Abstract] [Full Text] [Related]

  • 31. FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.
    Evangelista L, Redana S, Racca M, Geuna E, Vinante L, Zago G, De Carolis V, Ghiotto C, Saladini G, Varetto T.
    Clin Nucl Med; 2014 Feb 01; 39(2):e135-41. PubMed ID: 24398430
    [Abstract] [Full Text] [Related]

  • 32. Baseline and early 18F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapy.
    Lasnon C, Morel A, Aide N, Silva AD, Emile G.
    Cancer Imaging; 2024 Jul 09; 24(1):90. PubMed ID: 38982546
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 35. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 Dec 18; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 36. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.
    J Nucl Med; 2015 Jun 18; 56(6):824-31. PubMed ID: 25883123
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.
    Breast Cancer Res Treat; 2012 Aug 18; 135(1):231-40. PubMed ID: 22872522
    [Abstract] [Full Text] [Related]

  • 39. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.
    J Nucl Med; 2012 Sep 18; 53(9):1337-44. PubMed ID: 22870824
    [Abstract] [Full Text] [Related]

  • 40. 18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.
    Makhlin I, Korhonen KE, Martin ML, Gillman J, Schubert E, Pantel AR, Mankoff DA, Clark AS.
    Radiol Imaging Cancer; 2022 Nov 18; 4(6):e220032. PubMed ID: 36269154
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.